Acadian Asset Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-78,218
| Closed | -$197K | – | 2474 |
|
|
2020
Q2 | $197K | Buy |
+78,218
| New | +$148K | ﹤0.01% | 1496 |
|
|
2020
Q1 | – | Sell |
-671
| Closed | -$2K | – | 2019 |
|
|
2019
Q4 | $2K | Sell |
671
-6,137
| -90% | -$19.7K | ﹤0.01% | 1804 |
|
|
2019
Q3 | $37K | Sell |
6,808
-19,187
| -74% | -$128K | ﹤0.01% | 1655 |
|
|
2019
Q2 | $250K | Sell |
25,995
-2,016
| -7% | -$37.1K | ﹤0.01% | 1176 |
|
|
2019
Q1 | $750K | Buy |
28,011
+8,747
| +45% | +$223K | ﹤0.01% | 995 |
|
|
2018
Q4 | $436K | Sell |
19,264
-2,410
| -11% | -$94.2K | ﹤0.01% | 938 |
|
|
2018
Q3 | $1.2M | Buy |
21,674
+19,585
| +938% | +$1.25M | ﹤0.01% | 680 |
|
|
2018
Q2 | $149K | Sell |
2,089
-6,106
| -75% | -$431K | ﹤0.01% | 1150 |
|
|
2018
Q1 | $503K | Buy |
+8,195
| New | +$719K | ﹤0.01% | 861 |
|
|
2017
Q3 | – | Sell |
-6,359
| Closed | -$907K | – | 1610 |
|
|
2017
Q2 | $907K | Sell |
6,359
-12,593
| -66% | -$1.95M | ﹤0.01% | 725 |
|
|
2017
Q1 | $3.48M | Buy |
18,952
+9,851
| +108% | +$1.1M | 0.02% | 489 |
|
|
2016
Q4 | $734K | Buy |
9,101
+7,059
| +346% | +$558K | ﹤0.01% | 780 |
|
|
2016
Q3 | $157K | Sell |
2,042
-957
| -32% | -$76.7K | ﹤0.01% | 1001 |
|
|
2016
Q2 | $257K | Buy |
+2,999
| New | +$275K | ﹤0.01% | 881 |
|
Acadian Asset Management's TTPH Position: Q3 2020 in Review
Acadian Asset Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2020, closing a stake of 78,218 shares — an estimated $197K sold.
Acadian Asset Management first reported a position in TTPH in Q2 2016 and held it in 14 quarters. The position peaked at $3.48M in Q1 2017. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.
- Acadian Asset Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Acadian Asset Management sold 78,218 Tetraphase Pharmaceuticals, Inc. shares in Q3 2020, an estimated $197K.
- Acadian Asset Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2016 and held it in 14 quarters.
- Acadian Asset Management's Tetraphase Pharmaceuticals, Inc. position peaked at $3.48M in Q1 2017.
- 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2020.
Based on Acadian Asset Management's 13F filing for Q3 2020, filed 9 Nov 2020.